Login to Your Account



Other News To Note


Monday, December 3, 2012
• Exelixis Inc., of South San Francisco, said the European Medicines Agency accepted for review the marketing authorization application for Cometriq (cabozantinib) for the proposed indication of progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription